Table 1.
Baseline characteristics
| Placebo group (n=106) | Losartan group (n=105) | ||
|---|---|---|---|
| Sex | |||
| Male | 67 (63%) | 60 (57%) | |
| Female | 39 (37%) | 45 (43%) | |
| Ethnicity | |||
| White | 106 (100%) | 104 (99%) | |
| Other | 0 | 1 (1%) | |
| Age, years | |||
| <70 | 39 (37%) | 39 (37%) | |
| 70–79 | 42 (40%) | 39 (37%) | |
| >79 | 25 (24%) | 27 (26%) | |
| Hypertensive | 50 (47%) | 47 (45%) | |
| Education*, years | 12 (11–16) | 12 (10–16) | |
| Systolic blood pressure†, mm Hg | 136 (15) | 138 (13) | |
| Diastolic blood pressure†, mm Hg | 78 (8) | 79 (9) | |
| Years since diagnosis | 1·10 (0·69–2·43) | 1·38 (0·64–2·29) | |
| Total brain volume, mL | 1036 (111) | 1022 (99) | |
| Total intracranial volume, mL | 1459 (146) | 1440 (140) | |
| Lateral ventricle volume, mL | 47 (35–64) | 48 (35–69) | |
| Total hippocampal volume, mL | 5·0 (1·0) | 5·2 (0·9) | |
| Left hippocampal volume, mL | 2·5 (0·5) | 2·5 (0·5) | |
| Right hippocampal volume, mL | 2·6 (0·5) | 2·6 (0·5) | |
| Scheltens score | |||
| Absent or low (0–1) | 62 (58%) | 62 (59%) | |
| Moderate or severe (2–4) | 44 (42%) | 43 (41%) | |
| ADAS-cog‡ | 19 (7) | 20 (8) | |
| MMSE§ | 22 (3) | 22 (4) | |
| NPI | 6 (2–15) | 8 (3–18) | |
| BADLS | 5 (2–9) | 7 (2–13) | |
| DEMQOL | 96 (85–102) | 96 (87–102) | |
| DEMQOL-proxy | 92 (83–99) | 91 (82–100) | |
Data are n (%), median (IQR), or mean (SD). ADAS-cog=Alzheimer's Disease Assessment Scale–cognitive subscale. MMSE=Mini-Mental State Examination. NPI=Neuropsychiatric Inventory. BADLS=Bristol Activities of Daily Living Scale. DEMQOL=dementia quality of life. DEMQOL-proxy=carer-reported version of DEMQOL.
*
In the intervention group, data were available for only 100 patients.
†
Data were available for 84 patients in the placebo group and 83 patients in the losartan group.
‡
Data were available for 104 patients in the placebo group and 103 patients in the losartan group.
§
In the intervention group, data were available for only 103 patients.